ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Leah Lawrence

Leah Lawrence

Posts by Author

Patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with the checkpoint inhibitor nivolumab were able to maintain baseline levels of quality of life.

The US Food and Drug Administration has approved the optical imaging agent aminolevulinic acid hydrochloride to enhance visualization of malignant tissue during surgery for gliomas.

Adult patients with early thymic precursor (ETP) acute lymphoblastic leukemia (ALL), a subgroup of T-cell ALL, could benefit from the use of response-based risk stratification and therapy intensification similar to that used in pediatric patients with ETP-ALL.

Treatment with single-agent bevacizumab resulted in an improved disease-free interval in patients with resected melanoma, but no increase in overall survival compared with observation.

The primary tumor location was an independent prognostic marker in patients with RAS wild-type metastatic colorectal cancer after multivariable adjustment.

Long-term survivors of wild-type KRAS colorectal cancer tumors had significantly improved survival with regular use of nonsteroidal anti-inflammatory drugs.

Adding nintedanib to pemetrexed/cisplatin improved the progression-free survival of patients with malignant pleural mesothelioma compared with placebo.

Undergoing autologous hematopoietic stem cell transplantation was effective and safe in patients with refractory multiple myeloma, including those patients who are refractory to both proteasome inhibitors and immunomodulatory agents.

Patients with node-positive intermediate-thickness melanoma had an increased rate of regional disease control when undergoing completion lymph-node dissection for sentinel node metastases, however, there was no increase in melanoma-specific survival.

The FDA has approved daratumumab in combination with pomalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.